<DOC>
	<DOCNO>NCT02184260</DOCNO>
	<brief_summary>Clinical efficacy safety Metamizole 2 g i.v . versus placebo , antithermic therapy acute phase ischemic stroke .</brief_summary>
	<brief_title>Efficacy Safety Metamizole Versus Placebo Antithermic Therapy Acute Phase Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Dipyrone</mesh_term>
	<criteria>Age 18 year Hemispherical cerebral infarction moderate ( SSS = 3044 point ) severe ( SSS &lt; 30 point ) deficit time inclusion . However , patient score 15 44 point SSS scale include Tympanic temperature 37 38 degree Celsius . The relationship tympanic body temperature follow : tympanic temperature = body temperature + 0.3 degree Celsius Onset cerebral infarction symptom within last 24 hour . When time onset symptom unknown ( e.g . ictus occur sleep ) last time patient asymptomatic consider time onset Normal cerebral CT scan sign cerebral infarction Patient 's write orally witness informed consent accordance local legislation , guideline Good Clinical Practice ( GCP ) International Conference Harmonization ( ICH ) GCP Patients history granulocytopenia , thrombocytopenia aplastic blood disease etiology . Known hypersensitivity salicylate , pyrazolones nonsteroidal antiinflammatory drug ( NSAIDs ) . NSAIDinduced bronchial asthma Patients history indicate life expectancy le 30 day patient investigator think possible follow entire 30 day Noncooperative Patients neurological sequela previous stroke Cerebral hemorrhage Pregnancy , lactation Participation another clinical trial Intake acetylsalicylic acid ( ASA ) &gt; 300 mg per day , paracetamol NSAIDs 24 hour prior administration study medication Seizures start stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>